Related content

Pharmacogenetics of irinotecan: A promoter polymorphism of UGT1A1 gene and severe adverse reactions to irinotecan

By Ando Maki   Hasegawa Yoshinori   Ando Yuichi  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 539-545

Springer Publishing Company

Access to resources Recommend Favorite

UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine

By Goetz Matthew   McKean Heidi   Reid Joel   Mandrekar Sumithra   Tan Angelina   Kuffel Mary   Safgren Stephanie   McGovern Renee   Goldberg Richard   Grothey Axel   McWilliams Robert   Erlichman Charles   Ames Matthew  

Investigational New Drugs, Vol. 31, Iss. 6, 2013-12 ,pp. : 1559-1567

Springer Publishing Company

Access to resources Recommend Favorite

Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea

By Mehlotra Rajeev   Ziats Mark   Bockarie Moses   Zimmerman Peter  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 4, 2006-04 ,pp. : 267-275

Springer Publishing Company

Access to resources Recommend Favorite

Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients

By Kagaya Hideaki   Inoue Kazuyuki   Miura Masatomo   Satoh Shigeru   Saito Mitsuru   Tada Hitoshi   Habuchi Tomonori   Suzuki Toshio  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 3, 2007-03 ,pp. : 279-288

Springer Publishing Company

Access to resources Recommend Favorite

Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7

By Tsoutsikos P.   Miners J.O.   Stapleton A.   Thomas A.   Sallustio B.C.   Knights K.M.  

Biochemical Pharmacology, Vol. 67, Iss. 1, 2004-01 ,pp. : 191-199

Elsevier

Access to resources Recommend Favorite